Strategic leadership Recent CEO appointment signals potential strategic pivots and renewed focus on fundraising and growth in the near term, creating opportunities for executive outreach and alignment on partnerships and collaboration discussions.

Clinical capabilities Innovative atbody biologic platform and plant-based manufacturing suggest potential collaborations in antibody therapies, contract research, or manufacturing partnerships to leverage faster, single-step production processes.

Funding momentum Significant Series A funding and ongoing investor interest indicate a readiness to engage in partnerships, licensing discussions, and co-development deals to accelerate pipeline advancement.

Global collaboration Former iBio partnership and Belgium base imply openness to international manufacturing and development collaborations, enabling outreach to contract manufacturing and development organizations for scaled production.

Digital footprint Current tech stack and online presence provide entry points for targeting IT-enabled partnerships, such as enterprise software vendors, data analytics, and compliance solutions that support R&D workflows and regulatory readiness.